Q2 Earnings Forecast for PolyPid Issued By Roth Capital

PolyPid Ltd. (NASDAQ:PYPD) – Research analysts at Roth Capital issued their Q2 2025 earnings per share (EPS) estimates for shares of PolyPid in a research report issued to clients and investors on Thursday, June 5th. Roth Capital analyst B. Pachaiyappan forecasts that the company will post earnings of ($0.47) per share for the quarter. Roth Capital currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. Roth Capital also issued estimates for PolyPid’s Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.87) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.68) EPS.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.10.

Separately, HC Wainwright boosted their price target on PolyPid from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Monday. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $11.25.

PolyPid Stock Performance

NASDAQ:PYPD opened at $3.50 on Monday. The stock has a fifty day moving average price of $2.76 and a 200-day moving average price of $2.92. The company has a market cap of $35.67 million, a price-to-earnings ratio of -0.70 and a beta of 1.25. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.00 and a current ratio of 1.31. PolyPid has a fifty-two week low of $2.30 and a fifty-two week high of $4.49.

Institutional Investors Weigh In On PolyPid

Several institutional investors and hedge funds have recently made changes to their positions in PYPD. J. Goldman & Co LP bought a new stake in shares of PolyPid during the 4th quarter valued at about $391,000. AIGH Capital Management LLC boosted its position in shares of PolyPid by 21.8% during the 4th quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after purchasing an additional 148,199 shares in the last quarter. Finally, Rosalind Advisors Inc. boosted its position in shares of PolyPid by 49.9% during the 4th quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock valued at $3,095,000 after purchasing an additional 338,853 shares in the last quarter. Institutional investors own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.